Literature DB >> 8648738

Repression of human immunodeficiency virus type 1 long terminal repeat-driven gene expression by binding of the virus to its primary cellular receptor, the CD4 molecule.

P Bérubé1, B Barbeau, R Cantin, R P Sékaly, M Tremblay.   

Abstract

We have previously postulated that the binding of the human immunodeficiency virus type 1 (HIV-1) to cell surface CD4 induces signal transduction pathways that down-modulate production of progeny virions in acutely infected T cells (M. Tremblay, S. Meloche, S. Gratton, M. A. Wainberg, and R.-P. Sékaly, EMBO J. 13:774-783, 1994). To evaluate the possibility that CD4 cross-linking might indeed affect viral gene expression, we have introduced a molecular construct made of the luciferase reporter gene placed under the control of the regulatory elements of HIV-1 in several CD4-positive T-cell lines. We found that cross-linking of CD4 with defective HIV-1 particles and heat-inactivated viruses inhibits long terminal repeat-dependent luciferase expression. Experiments revealed that the gp120-CD4 interaction was necessary to repress HIV-1 long terminal repeat-dependent luciferase activity. The cytoplasmic domain of CD4 was also found to be required for this effect to occur. The virus-mediated signal transduction was shown to be mediated via p56lck-dependent and -independent pathways. These results indicate that the earliest event in the HIV-1 replicative cycle, namely, the binding of the virus to its cellular receptor, can lead to signal transduction culminating in down-modulation of viral gene expression. Thus we propose that defective viruses could regulate the pathogenesis of HIV disease as they constitute the vast majority of circulating HIV-1 particles.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8648738      PMCID: PMC190279     

Source DB:  PubMed          Journal:  J Virol        ISSN: 0022-538X            Impact factor:   5.103


  81 in total

1.  Internalization of HIV glycoprotein gp120 is associated with down-modulation of membrane CD4 and p56lck together with impairment of T cell activation.

Authors:  D Cefai; M Ferrer; N Serpente; T Idziorek; A Dautry-Varsat; P Debre; G Bismuth
Journal:  J Immunol       Date:  1992-07-01       Impact factor: 5.422

Review 2.  NF-kappa B: a pleiotropic mediator of inducible and tissue-specific gene control.

Authors:  M J Lenardo; D Baltimore
Journal:  Cell       Date:  1989-07-28       Impact factor: 41.582

3.  Crosslinking of surface antigens causes mobilization of intracellular ionized calcium in T lymphocytes.

Authors:  J A Ledbetter; C H June; L S Grosmaire; P S Rabinovitch
Journal:  Proc Natl Acad Sci U S A       Date:  1987-03       Impact factor: 11.205

4.  Induction of HTLV-III/LAV from a nonvirus-producing T-cell line: implications for latency.

Authors:  T Folks; D M Powell; M M Lightfoote; S Benn; M A Martin; A S Fauci
Journal:  Science       Date:  1986-02-07       Impact factor: 47.728

5.  Binding of the human retrovirus HTLV-III/LAV/ARV/HIV to the CD4 (T4) molecule: conformation dependence, epitope mapping, antibody inhibition, and potential for idiotypic mimicry.

Authors:  J S McDougal; J K Nicholson; G D Cross; S P Cort; M S Kennedy; A C Mawle
Journal:  J Immunol       Date:  1986-11-01       Impact factor: 5.422

6.  The role of L3T4 in T cell activation: L3T4 may be both an Ia-binding protein and a receptor that transduces a negative signal.

Authors:  J P Tite; A Sloan; C A Janeway
Journal:  J Mol Cell Immunol       Date:  1986

7.  Loss of envelope antigens of HTLV-III/LAV, a factor in AIDS pathogenesis?

Authors:  H R Gelderblom; H Reupke; G Pauli
Journal:  Lancet       Date:  1985-11-02       Impact factor: 79.321

8.  Detection of lymphocytes expressing human T-lymphotropic virus type III in lymph nodes and peripheral blood from infected individuals by in situ hybridization.

Authors:  M E Harper; L M Marselle; R C Gallo; F Wong-Staal
Journal:  Proc Natl Acad Sci U S A       Date:  1986-02       Impact factor: 11.205

9.  Binding of HTLV-III/LAV to T4+ T cells by a complex of the 110K viral protein and the T4 molecule.

Authors:  J S McDougal; M S Kennedy; J M Sligh; S P Cort; A Mawle; J K Nicholson
Journal:  Science       Date:  1986-01-24       Impact factor: 47.728

10.  Inhibition of virus production in peripheral blood mononuclear cells from human immunodeficiency virus (HIV) type 1-seropositive donors by treatment with recombinant HIV-like particles.

Authors:  O K Haffar; P A Moran; M D Smithgall; M L Diegel; P Sridhar; J A Ledbetter; J M Zarling; S L Hu
Journal:  J Virol       Date:  1992-07       Impact factor: 5.103

View more
  9 in total

1.  The presence of host-derived HLA-DR1 on human immunodeficiency virus type 1 increases viral infectivity.

Authors:  R Cantin; J F Fortin; G Lamontagne; M Tremblay
Journal:  J Virol       Date:  1997-03       Impact factor: 5.103

2.  In vitro and in vivo evaluations of sodium lauryl sulfate and dextran sulfate as microbicides against herpes simplex and human immunodeficiency viruses.

Authors:  J Piret; J Lamontagne; J Bestman-Smith; S Roy; P Gourde; A Désormeaux; R F Omar; J Juhász; M G Bergeron
Journal:  J Clin Microbiol       Date:  2000-01       Impact factor: 5.948

3.  Delayed human immunodeficiency virus type 1-induced apoptosis in cells expressing truncated forms of CD4.

Authors:  C Guillerm; N Coudronnière; V Robert-Hebmann; C Devaux
Journal:  J Virol       Date:  1998-03       Impact factor: 5.103

4.  Host-derived ICAM-1 glycoproteins incorporated on human immunodeficiency virus type 1 are biologically active and enhance viral infectivity.

Authors:  J F Fortin; R Cantin; G Lamontagne; M Tremblay
Journal:  J Virol       Date:  1997-05       Impact factor: 5.103

5.  MAVS dimer is a crucial signaling component of innate immunity and the target of hepatitis C virus NS3/4A protease.

Authors:  Martin Baril; Marie-Eve Racine; François Penin; Daniel Lamarre
Journal:  J Virol       Date:  2008-11-26       Impact factor: 5.103

6.  Genome-wide RNAi screen reveals a new role of a WNT/CTNNB1 signaling pathway as negative regulator of virus-induced innate immune responses.

Authors:  Martin Baril; Salwa Es-Saad; Laurent Chatel-Chaix; Karin Fink; Tram Pham; Valérie-Ann Raymond; Karine Audette; Anne-Sophie Guenier; Jean Duchaine; Marc Servant; Marc Bilodeau; Eric Cohen; Nathalie Grandvaux; Daniel Lamarre
Journal:  PLoS Pathog       Date:  2013-06-13       Impact factor: 6.823

7.  Signal transduction due to HIV-1 envelope interactions with chemokine receptors CXCR4 or CCR5.

Authors:  C B Davis; I Dikic; D Unutmaz; C M Hill; J Arthos; M A Siani; D A Thompson; J Schlessinger; D R Littman
Journal:  J Exp Med       Date:  1997-11-17       Impact factor: 14.307

8.  Spliceosome SNRNP200 Promotes Viral RNA Sensing and IRF3 Activation of Antiviral Response.

Authors:  Nicolas Tremblay; Martin Baril; Laurent Chatel-Chaix; Salwa Es-Saad; Alex Young Park; Robert K Koenekoop; Daniel Lamarre
Journal:  PLoS Pathog       Date:  2016-07-25       Impact factor: 6.823

Review 9.  Application of proteomics technology for analyzing the interactions between host cells and intracellular infectious agents.

Authors:  Mayte Coiras; Emilio Camafeita; María Rosa López-Huertas; Enrique Calvo; Juan Antonio López; José Alcamí
Journal:  Proteomics       Date:  2008-02       Impact factor: 3.984

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.